SKIN PROTECTION
Materials and methods IgE release CD19+B cells were cultured for 2 hours either in assay medium alone or in medium containing the new yeast cell active. To mimic a Th2 response, cells were treated with a mix of anti-CD40 and the cytokine IL-4 to stimulate IgE production for 14 days. Quantification of secreted IgE antibodies was carried out by ELISA.
IL-8 release Reconstructed human epidermis (RHE) was pre-treated with assay medium alone or medium containing the new yeast cell active for 2 hours. This was followed by a 24-hour treatment with a mixture of the cytokines IL-4/IL-13/IL-22/TNF-α. IL-8 expression was quantified by RT-qPCR.
Staphylococcus aureus adhesion to reconstructed human epidermis RHE was pretreated by topical application on the surface of the epidermis of either the new yeast cell active or PBS solution as a control for 2 hours at room temperature. The RHE surface was cleaned and either topically treated with the new yeast cell active and radiolabelled S. aureus bacteria or PBS and radiolabelled S. aureus for 1 hour. RHEs were washed and remaining radioactivity was measured by liquid scintillation counting.
Clinical studies Skin parameter measurements: A double- blind clinical trial was performed with 20 volunteers (average age 44 years) diagnosed with AD but free of symptoms during the study. They applied a placebo cream on the inner side of one forearm and the same cream containing 0.1% new yeast cell active on the inner side of the other forearm twice daily for 28 days. After 14 and 28 days, skin hydration,
10
n Initial conditions n 0.04% MgCM-Glucan
8
*p<0.05 vs. initial conditions **p<0.01 vs. initial conditions
20
n Placebo n 0.1% MgCM-Glucan
*p<0.05 vs. untreated **p<0.05 vs. untreated and placebo 15 –4 * 10 * ** –2 0
–6 –8 5 –10 *p<0.05 vs. untreated
n Placebo n 0.1% MgCM-Glucan
0 Day 14 Day 28
Figure 5: Increase in skin smoothness after 14 and 28 days treatment with placebo cream or a cream containing 0.1% MgCM-Glucan.
roughness and TEWL were measured using a Corneometer MPA5 CPU, PRIMOS and Tewameter TM210, respectively. Self-assessment: 10 volunteers
(average age 58 years) with AD applied an aqueous solution containing 0.04% new yeast cell active on an area with eczematous skin twice daily for 7 days. Before and after the study, volunteers filled out a questionnaire about their skin condition on the treated area, giving scores on a 10-point scale.
Results and discussion Reduction of Th2 response in atopic dermatitis models To test whether the new yeast cell active is indeed able to suppress the Th2 immune response, B cells were stimulated to produce IgE to mimic
–12 Day 14 Day 28
Figure 6: Decrease in TEWL after 14 and 28 days treatment with placebo cream or a cream containing 0.1% MgCM-Glucan.
Th2 activation. Treatment with the new yeast cell active reduced IgE production by 26%. Using reconstructed human epidermis
(RHE), IL-8 production was stimulated by treatment with a mixture of pro- inflammatory cytokines. Expression of IL-8 was decreased by 53% in the RHE when pretreated with the new yeast cell active compared to stimulated but not pretreated samples. Together this shows that the new yeast cell active is able to reduce the expression of two players in the inflammatory response in vitro that can lead to skin eczema.
Impaired binding of bacteria to the skin In AD skin, the chronic inflammation is often exacerbated by bacterial infection,
*
*
6 ** 4 * 2 ** * ** **
0 Itching Irritation Tension Dryness Redness
Figure 7: Skin condition parameters as evaluated by self assessment before and after one week’s treatment with an aqueous solution containing 0.04% MgCM-Glucan.
66 PERSONAL CARE February 2016 Roughness
Self assessment scoring of skin parameters
Increase in skin smoothness (%)
Decrease in TEWL (%)
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76
